T1	intervention 12 21	denosumab
T2	condition 43 63	bone mineral density
T3	eligibility 636 791	postmenopausal patients scheduled to receive letrozole or anastrozole as a postoperative endocrine therapy for stage I-IIIA hormone-sensitive breast cancer
T4	control 798 811	control group
T5	duration 932 939	5 years
T6	outcome-Measure 1148 1194	rate of change in the lumbar spine (L1-L4) BMD
T7	outcome-Measure 1326 1350	ETHICS AND DISSEMINATION
